The Rise of K-Biotech CDMOs (Samsung Biologics & SK)
South Korea’s strategic advantage in 2026 lies in its Contract Development and Manufacturing Organizations (CDMOs).
Companies like Samsung Biologics and SK pharmteco have transitioned from antibody production to becoming global leaders in viral vector manufacturing (specifically AAV and Lentivirus). In 2026, Samsung Biologics’ Songdo facility has dedicated "Super-Plants" for cell and gene therapy (CGT), offering global pharmaceutical companies a scalable, GMP-compliant hub. This infrastructure has allowed South Korea to capture a significant portion of the global gene therapy supply chain, reducing the "manufacturing bottleneck" that previously delayed clinical trials worldwide.
1 View